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Background: Few large-scale, real-world studies have assessed the relative associations of lipid fractions with
diabetic microvascular events. The main objective of this study was to evaluate the association of the lipid profile
components, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides
(TG), and non-high density lipoprotein cholesterol (non-HDL-C) with microvascular complications (MVCs) in type 2
diabetes mellitus (T2DM) patients.
Methods: This observational cohort study queried the HealthCore Integrated Research Database (HIRDSM) for
newly-diagnosed (Index Date) 18-64-year-old patients with diabetes mellitus between 01/01/2005-06/30/2010.
Inclusion required ≥12 months pre-index continuous health plan eligibility and ≥1 pre-index lipid profile result.
Patients with polycystic ovary syndrome and prior MVCs were excluded. Incident complications were defined as the
earliest occurrence of diabetic retinopathy, peripheral neuropathy, and/or nephropathy post-index. Cox proportional
models and Kaplan-Meier (KM) curves were used to evaluate associations among variables.
Results: Of the patients (N = 72,267), 50.05 % achieved HDL-C, 64.28 % LDL-C, 59.82 % TG, and 56.79 % non-HDL-C
American Diabetes Association goals at baseline. During follow-up (mean, 21.74 months), there were 5.21
microvascular events per 1,000 patient-months. A 1-mg/dL increase in HDL-C was associated with 1 % decrease in
any MVC risk (P< .0001), but for LDL-C, TG, and non-HDL-C, 1-mg/dL increase resulted in increases of 0.2 %
(P< .0001), 0.1 % (P< 0.001) and 0.3 % (P< 0.001) in MVC risk. Patients achieving HDL-C goals had a 11 % lower risk
of MVC versus non-achievers (RR 0.895, [95 % CI, 0.852-0.941], P< .0001). Similarly, TG goal attainment was
associated with a lowered risk for any MVC (RR 0.849, [95 % CI, 0.808-0.892], P< .0001). Evaluation of KM survival
curves demonstrated no significant difference in the risk of MVCs between patients achieving vs. not achieving
LDL-C goals, but did demonstrate a difference in MVC risk between patients achieving vs. not achieving non-HDL-C
goals.
Conclusion: This study demonstrates significant independent associations among lipid fractions and risk for
microangiopathy. These findings suggest that attaining established ADA goals for HDL-C, TG, and non-HDL-C may
reduce risk for microvascular events among patients with diabetes.
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An estimated 25.8 million people, or 8.3 % of the US
population, were affected by diabetes mellitus in 2010,
with 90 %-95 % afflicted with type 2 (T2DM). The
American Diabetes Association (ADA) and American
Heart Association (AHA) attribute substantial patient
morbidity and mortality to T2DM [1]. Furthermore,
T2DM is associated with multiple microvascular com-
plications (MVCs) including retinopathy, neuropathy,
and nephropathy, all of which contribute to diabetes-
associated morbidity and mortality [2,3]. From 2005–
2008, 4.2 million patients with diabetes had diabetic retin-
opathy, 655,000 of whom developed serious vision loss [4]
for a total annual cost of $492.98 million [5]. Diabetic
neuropathy affects an estimated 12 %-50 % of those with
diabetes, with total annual costs estimated at $10.1 billion.
As many as 19 % of T2DM patients have nephropathy
and end-stage renal disease, with annual medical costs in
the US amounting to about $15 billion [6].
Elevated serum levels of low-density lipoprotein choles-
terol (LDL-C) and triglycerides (TG) and low levels of
high-density lipoprotein cholesterol (HDL-C) are strongly
associated with increased risk for macrovascular events
(e.g., myocardial infarction, ischemic stroke, and coronary
mortality) among patients with T2DM [3,7,8]. However,
no consensus exists on possible mechanisms linking these
individual lipid subfractions to MVCs. A systematic review
of studies assessing associations between lipid subfractions
and MVCs noted that dyslipidemia may cause or worsen
complications [3]. A European study reported significant
associations between elevated levels of total cholesterol
(TC) and lower levels of HDL-C with increasing severity
of diabetic retinopathy; there was, however, no apparent
association between serum TG and retinopathy [9]. An-
other study found high levels of TC and TG associated
with diabetic nephropathy and declining kidney function
[10]. The relationship between abnormal lipid subfractions
and diabetic neuropathy is relatively unexplored, with only
one study showing a small degree of association [11].
Most studies seeking to establish associations between
dyslipidemia and microvascular events were of short dur-
ation with relatively small sample sizes, rendering them
underpowered and with limited generalizability [3]. Never-
theless, available evidence indicates abnormalities among
lipid subfractions exacerbate the risk of microvascular
events [9].
To date, few studies have investigated the relative mag-
nitude of association between individual lipid subfractions
and diabetes-related MVCs. Furthermore, comprehensive
literature reviews have not revealed any large-scale real-
world studies that assessed the relative associations of
standard lipid fractions with diabetic MVCs. In recogni-
tion of that gap, this study accessed data from a managed
care database to evaluate associations between the levels oflipid subfractions (LDL-C, HDL-C, TG, and non-HDL-C)
and the incidence of diabetic retinopathy, peripheral neur-
opathy, and nephropathy. The impact on risk for MVCs
following attainment of ADA targets for specific compo-
nents of the lipid profile was also quantified [12].
Methods
Data source and study design
This observational cohort study utilized integrated medical,
pharmacy, and laboratory result data from the HealthCore
Integrated Research DatabaseSM (HIRDSM) between
01/01/04-06/30/2010. The HIRDSM contains administrative
claims data for more than 35 million Americans covered by
14 geographically dispersed commercial US healthcare
plans. All information utilized in this retrospective, longitu-
dinal analysis was managed in strict compliance with
the Health Insurance Portability and Accountability
Act (HIPAA) of 1996. Patient confidentiality and ano-
nymity was preserved via de-identification throughout
the study.
Inclusion criteria
Patients newly diagnosed with T2DM (index date) involv-
ing a medical claim with an International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) diagnosis code for 250.x0 or 250.x2 or a pharmacy
claim with a GPI for an antidiabetic agent between 01/01/
2005 and 06/30/2010 were identified. The index date was
the earliest point of onset of T2DM. To be included,
patients aged between 18-to-64 years were required to
have ≥12 months of continuous health plan eligibility pre-
ceding the index date and ≥1 full lipid panel during the
12-month pre-index date period, the most current of
which was defined as the baseline lipid panel.
Exclusion criteria
Patients with a history of T2DM or any pre-index med-
ical claim for diabetic retinopathy, neuropathy, or
reduced kidney function were excluded. Also excluded
were patients with a medical claim for polycystic ovary
syndrome (ICD-9-CM: 256.4x) any time during the
study period.
Definition of follow-up
Follow-up was defined as the period between the index
date and the earliest of the following: end of continuous
health plan eligibility, end of the available data stream
(06/30/2010), or a censoring event. For each outcome
of interest, data were censored at the earliest occurrence
of the event of interest, when patients reached 65 years of
age, or a death was recorded in the Social Security Death
Index Master File. Adjustments in the amount of person-
time contributed during follow-up were made whenever
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durations.MVCs
The MVCs of interest were diabetic neuropathy, retinop-
athy, and nephropathy identified during any inpatient,
outpatient, or emergency room visit using ICD-9-CM
diagnoses and procedure codes, Current Procedural Ter-
minology (CPT) codes, and revenue service codes from
patients’ medical claims. Nonspecific diagnoses of neur-
opathy and nephropathy were considered to be T2DM-
attributable MVCs provided a T2DM diagnosis code was
recorded on the same medical claim date. In addition,
diabetic nephropathy was also identified using glomeru-
lar filtration rates (eGFR) estimated from the serum cre-
atinine laboratory values. An abbreviated Modification
of Diet and Renal Disease (MDRD) equation was used to
calculate eGFR since information on race was lacking
[13]. An eGFR of <60 mL/min was defined as reduced
kidney function, although this may not necessarily be
attributable to diabetes. As a result, any eGFR-identified
overt nephropathy was only classified as diabetic nephro-
pathy if there was no prior medical claim for nonspecific
nephropathy.Lipid subfraction goals
Results from the last full lipid panel measurement before
the end of the follow-up period was used to evaluate the
relative association between each lipid subfraction and
the events of interest. The target level for each lipid frac-
tion was defined on the basis of ADA treatment guide-
lines for people with diabetes: LDL-C <100 mg/dL,
HDL-C >40 mg/dL for men and >50 mg/dL for women,
TG <150 mg/dL, and non-HDL-C <130 mg/dL [12]. As-
sessment of lipid goals as of the baseline lipid panel (i.e.,
preceding the onset of T2DM), were applied according
to the National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) Guidelines for non-
diabetic patients [13]. Depending on their risk category —
primary (2+ risk factors), secondary (cardiovascular
heart disease [CHD] or CHD risk equivalents), or non-
determinant (0–1 risk factors) based on information avail-
able from their start date of continuous eligibility until the
day of the lipid panel measurement — the following rules
for goal attainment were applied: LDL-C <130 mg/dL and
<100 mg/dL for patients at primary and secondary risk,
respectively; HDL-C >40 mg/dL for men and >50 mg/dL
for women; TG <150 mg/dL for women (based on AHA
guidelines for women [14]) and <200 mg/dL for men; and
non-HDL-C <160 mg/dL and <130 mg/dL for patients at
primary and secondary risk, respectively. For patients with
an indeterminate risk status, baseline LDL-C and non-
HDL-C goal attainment could not be ascertained.Patient characteristics
Demographic characteristics included age, gender, geo-
graphic location, and type of health insurance coverage
on index date. Baseline comorbidities and the Deyo-
Charlson Comorbidity Index were evaluated during the
12-month pre-index period. The most recent lipid sub-
fractions of interest (LDL-C, HDL-C, TG, and non-
HDL-C) prior to the index date were used to describe
the baseline lipid panel.
Medication utilization patterns were assessed for anti-
glycemic, antihypertensive, and lipid-altering therapies at
baseline and follow-up. Exposure to both antidiabetic and
antihypertensive agents (angiotensin-converting enzyme
[ACE] inhibitors and angiotensin receptor blockers
[ARBs]) during follow-up was measured based on the pro-
portion of days covered (PDC) [15,16]. Exposure to lipid-
altering therapies, such as statins, niacin, and fibrates
(fenofibrate and gemfibrozil), as of the latest available full
lipid laboratory panel prior to the end of follow-up. Was
evaluated to adjust for potential changes in lipid values




Continuous characteristics were represented using
means and standard deviations, while categorical vari-
ables were evaluated as percentages. All right-censored
continuous outcomes were compared by means of un-
adjusted Cox proportional hazards models and the log
rank test. Kaplan-Meier (KM) curves were constructed
to evaluate the risk of MVCs between patients achieving
and not achieving goals for each lipid subfraction.
Multivariate analysis
Four Cox proportional hazards models were developed to
determine the relative significance of lipid subfraction
levels and goal attainment on the risk of MVCs. Add-
itional covariates included age, gender, state of residence,
health plan, and physician type. Also included were pre-
index health conditions (hypertension, obesity, heart failure,
metabolic syndrome, renal disease, liver disease, ischemic
heart disease, peripheral vascular disease, and depression)
and PDC during follow-up for antihypertensives (ACEs and
ARBs) and lipid-altering therapies (statins, niacin, ezeti-
mibe, and fibrates).
Sensitivity analysis
Additional univariate assessments were performed to de-
termine if the observed associations between TG/HDL
and MVCs remained unchanged or attenuated once TG
was adjusted for HDL-C or vice versa by computing the
variance inflation factor (VIF) and condition index. A
value of 10 and 30 respectively were set apriori to
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further investigate the relative importance of the man-
agement of other lipid measures beyond LDL-C alone
with respect to MVC risk, the risk of MVCs among
patients achieving LDL-C goals only vs. those simultan-
eously achieving HDL-C and LDL-C goals was evalu-
ated. Similar comparisons were conducted between
those achieving LDL-C goal only vs. those simultan-
eously achieving dual goals of LDL-C and TG, HDL-C
and TG and non-HDL-C goals respectively. Further-
more, the above analyses were replicated among those
who did not attain LDL-C treatment goals to evaluate
the impact of HDL-C, TG, and Non-HDL-C goal
achievement in the absence of LDL-C goal achievement.
Results
Demographic and clinical characteristics at baseline
Of the patients (N= 72,267) in this study, 48.7 % were
females, and the overall mean (±SD) age was 49.91
(±9.44) years (Table 1). At baseline, the mean (±SD) lipid
panel values for all patients were 115.71 (±35.65) for
LDL-C, 47.28 (±13.90) for HDL-C, 186.69 (±176.52) for
TG, and 150.61 (±43.53) for non-HDL-C. Overall,
50.05 % of the patients attained their HDL-C goals,
while 59.82 % reached their TG goals at baseline. Based
on a subsample of 37,118 patients for whom CHD risk
status and corresponding LDL-C and non-HDL-C goals
could be determined, 64.28 % of the patients attained
their LDL-C goals, while 56.79 % reached their non-
HDL-C goals at baseline.
Follow-up medication utilization
Assessment of medication utilization during follow-up
revealed no significant differences between any medica-
tion class (i.e., antiglycemic, antihypertensive, and lipid-
altering drugs) irrespective of whether patients had or
did not have an MVC event for any of the lipid
subfractions.
Follow-up MVC incidence rate
On the basis of 1000 patient-months, the incidence rate
for any microvascular event was 5.21 (95 % CI, 5.09-
5.33). Incidence rates were 1.44 (95 % CI, 1.38-1.50) for
diabetic retinopathy; 1.26 (95 % CI, 1.20-1.32) for dia-
betic neuropathy; and 2.61 (95 % CI, 2.53-2.69) for dia-
betic nephropathy.
Follow-up Lipid Subfractions
As of the last full lipid panel measurement during fol-
low-up, the mean HDL-C, TG, and non-HDL-C values
for patients who experienced any MVC event were sig-
nificantly different compared with patients with no
events (P < .0001; Table 2). The mean HDL-C values in
the total population was 48.02 (±14.13); for patients withan observed MVC event, the mean HDL-C was 46.72
(±14.04); and for patients without events, 48.16 (±14.13,
P < .0001). The mean LDL-C values for patients who
experienced MVC events versus those with no event
were not significantly different.
LDL-C goal attainment occurred more frequently
among patients with events (43.8 %) versus those who
had no event (41.86 %, P= .0015). Patients who experi-
enced an MVC event were less likely to have attained
their HDL-C and TG goals (48.51 % and 54.30 %, re-
spectively) compared with patients with no event
(52.96 % and 60.97 %, for HDL-C and TG, respectively,
P < .001). There was no significant difference in the pro-
portion of patients achieving non-HDL-C goals between
patients with MVC events (41.70 %) compared with
those with no events (42.63 %, P= .1299).Univariate and multivariate comparisons between lipid
subfractions and MVCs
MVC incidence rates per 1000 patient-months were
evaluated for each lipid subfraction based on the labora-
tory values from the last tests before the first event or
censorship.LDL-C
The MVC incidence rate for patients who attained their
LDL-C goals was 5.17 per 1000 patient-months versus
5.24 for those who did not attain their LDL-C goals dur-
ing follow up. A unit increase in LDL-C was not asso-
ciated with a significant risk increase (RR 1.0, [95 % CI,
1–1.001], P= .3513). KM curves showed no significant
difference in risk for any MVC event and LDL-C goal at-
tainment (RR 1.011, [95 % CI, 0.965-1.059], P= .6522;
Figure 1). Multivariate Cox regression analysis, however,
demonstrated significant associations between LDL-C
levels (RR 1.002, [95 % CI, 1.001-1.002], P < .0001) and
LDL-C goal attainment (RR 0.909, [95 % CI, 0.865-
0.955], P= .0001) and MVC risk (Table 3).HDL-C
The MVC incidence rate was 4.73 per 1000 patient-
months for patients at their HDL-C goal versus 5.76 per
1000 patient-months who were not. Each unit increase in
HDL-C was associated with 1 % decrease in event risk (RR
0.992, [95 % CI, 0.99-0.994], P< .0001). Patients who
attained HDL-C goals had 17 % lower risk of any MVC
event versus those who did not (RR 0.83, [95 % CI, 0.793-
0.869], P< .0001; Figure 1). Adjusted analysis showed that
a one unit increase in HDL-C levels or HDL-C goal attain-
ment reduced MVC risk by 0.5 % (RR 0.995, [95 % CI,
0.993-0.997]; P< .0001) and 10.5 % (RR 0.895, [95 % CI,
0.852-0.941]; P< .0001), respectively.























General family practice 22,927 31.34






Goal attainment2 23,858 64.28
HDL-C 47.28 ±13.90
Goal attainment 36,171 50.05
TG 186.69 ±176.52
Goal attainment 43,230 59.82
nonHDL-C 150.61 ±43.53
Goal attainment2 21,081 56.79
Comorbidities




Heart failure 2,511 3.47
Cerebrovascular disease 2,023 2.80
Metabolic syndrome 1,940 2.68
Liver disease 1,932 2.67
Table 1 Baseline Characteristics of Patients in the Study
(Continued)
Peripheral vascular disease 1,554 2.15
Renal disease3 394 0.55
Schizophrenia 68 0.09
DCI score, mean± SD 0.34 ±0.9
Medication Use4
Antihypertensive Medications 14,387 19.91




Low Potency 2,422 3.35
Medium Potency 9,840 13.62






Days of Study Follow-up5, mean± SD 652.58 ±484.18
1 The lipid panel values are derived from the most recent lab assessment
results prior to the index date.
2 For LDL-C and non-HDL-C: Goal attainment based on subsample of 37,118
patients since 35,149 patients had no discernible risk at baseline.
3 Pre-index renal disease includes acute renal failure, hypertensive kidney
disease, and glomerulonephritis.
4 n and % of patients with any fill for medication of interest.
5 Number of days from index date to end of study follow up (defined as the
end of earliest occurrence of event of interest, death, patient becoming
65 years or older, end of health plan eligibility, or 6/30/2010).
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein
cholesterol; TG: triglycerides; ACE: angiotensin-converting enzyme; ARB:
angiotensin receptor blockers; HMO: health maintenance organization; PPO:
patient preferred organization; POS: point of service; FFS: fee for service.
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Patients achieving TG goal had an MVC incidence rate
of 4.71 per 1000 patient-months versus those who did
not (5.97). A unit increase in TG levels resulted in a
0.1 % greater risk of a MVC event (RR 1.001, [95 % CI,
1.001-1.001], P < .0001). Patients at TG goal were 11.3 %
less likely to have a microvascular complication versus
those not attaining target TG levels (RR 0.787, [95 % CI,
0.751-0.824], P < .0001; Figure 1). Multivariate regression
analysis also indicated significant associations between
TG levels (RR 1.001, [95 % CI, 1.001-1.001], P < .0001)
and TG goal achievement (RR 0.849, [95 % CI, 0.808-
0.892], P < .0001) and MVC risk.
Non-HDL-C
For patients achieving non-HDL-C goal, the MVC inci-
dence rate was 4.83 versus 5.52 per 1000 patient-months
for those not at goal. For each unit increase in non-
Table 2 Last Lipid Panel Results Prior to Any Microvascular Event or Censorship
Lipid Characteristics All Patients Event1 No Event2 P - Value3
N=72,267 n= 7,271 n= 64,996
# Days from Last Lipid Panel to Any
Microvascular Event/Censorship: mean± SD
346.21 ±351.43 148.40 ±223.94 368.34 ±356.15 <.0001
Lipid Panel Values: mean± SD
LDL-C 109.08 ±34.35 108.33 ±36.47 109.16 ±34.1 .0513
HDL-C 48.02 ±14.13 46.72 ±14.04 48.16 ±14.13 <.0001
Triglycerides 163.35 ±122 186.39 ±186.41 160.77 ±112.23 <.0001
Non-HDL-C 140.55 ±40.25 143.19 ±45.9 140.26 ±39.56 <.0001
Lipid Goal Attainment Results: n, row%
LDL-C 30,395 42.06 % 3,185 43.80 % 27,210 41.86 % .0015
HDL-C 37,946 52.51 % 3,527 48.51 % 34,419 52.96 % <.0001
Triglycerides 43,577 60.30 % 3,948 54.30 % 39,629 60.97 % <.0001
Non-HDL-C 30,737 42.53 % 3,032 41.70 % 27,705 42.63 % .1299
1For those patients who experienced any corresponding microvascular event of interest (diabetic retinopathy/nephropathy/neuropathy), mean values of the last
laboratory assessment prior to the first event are presented.
2For those patients who did not experience the microvascular event of interest (diabetic retinopathy/nephropathy/neuropathy), mean values of the last laboratory
assessment prior to censorship (death, age >64 years, end of plan eligibility, or data period) are presented.
3P-value between the event and no event groups is significant at < .05.
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.
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1.003, [95 % CI, 1.002-1.003], P< .0001). Patients who
attained non-HDL-C goal had 10 % lower risk for a micro-
vascular event compared with patients who did not (RR
0.90, [95 % CI, 0.859-0.943], P< .0001; Figure 1). Adjusted
Cox results indicated that non-HDL-C levels (RR 1.003,
[95 % CI, 1.003-1.004], P< .0001) and non-HDL-C goal
(RR 0.827, [95 % CI, 0.788-0.868], P< .0001) were signifi-
cantly associated with lowered MVC event risks.
Sensitivity analysis
The reported associations for TG and HDL lipid sub-
fractions remained free from any collinearity bias based
on the minor (<2) VIF and condition index values
observed for the lipid-subfractions in question. This
indicates that the associations between TG/HDL and
MVCs were not affected by the presence of other lipid
fractions in the same model. Irrespective of LDL-C treat-
ment goal achievement, significant independent reduc-
tions in MVC risk were found for those who attained
HDL-C, TG, HDL-C and TG and non-HDL-C goals ver-
sus those who did not achieve these goals (Table 4).
Discussion
Consistent with the available evidence on diabetic com-
plications [2,3,7,9-11,17,18], this study found significant
independent associations between HDL-C, LDL-C, TG,
and non-HDL-C and risks for MVC among patients with
T2DM in a real-world managed care population. Al-
though management of LDL-C is the primary goal of
therapy, our findings suggest further benefit may be
obtained by expanding treatment goals to includemodification of other lipid subfractions in addition to
LDL-C. These associations persisted after controlling for
numerous covariates, including comorbidities and con-
comitant medications.
A 1 mg/dL increase in HDL-C levels was associated
with a significant decrease (0.5 %) in the risk of MVCs.
Furthermore, patients who achieved HDL-C goals dur-
ing follow-up also reduced their risk for experiencing
MVCs by 10.5 %. These findings suggest that targeting
HDL-C in addition to LDL-C as recommended by NCEP
ATP III may have benefits beyond CHD risk reduction
[12]. In the case of TGs, a significant increase in risk
(0.1 %) for a MVC event was observed for a 1 mg/dL
increase in the serum levels of TG. Further under-
scoring the risks associated with suboptimal TG goals
[2,13,19,20], the study found TG goal attainment lowered
the risk of MVC by 15.1 %. The relationship of elevated
TG and/or reduced HDL-C levels with MVCs was re-
cently demonstrated by Zoppini et al., who showed a high
TG/HDL-C ratio approximately doubled the risk for
MVC over a 5-year period in 979 Caucasian patients with
T2DM [21]. In a prospective observational study of 6,499
patients with diabetes and dyslipidemia, Teramoto et al.
confirmed the importance of controlling TG and HDL-C
in conjunction with HbA1C levels in patients with T2DM
[22]. Taken together, these studies highlight the import-
ance of targeting atherogenic dyslipidemia as a means to
reduce MVCs in patients with T2DM. Our results further
extend these findings by emphasizing the need to treat
HDL-C and triglycerides to ADA defined targets in order
to beneficially impact risk for both macrovascular and
microvascular events.
Figure 1 Lipid Subfractions and any Microvascular Event.
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goals were positively and negatively associated with
MVC event risk, respectively in our study. However, the
KM curves between those achieving versus those not
achieving LDL-C goals were not statistically different
(P= .3513), indicating a lack of proportionality of MVC
event risk over time. LDL-C reduction does not appear
to mitigate risk for MVCs in diabetic patients.
Guidelines recommend non-HDL-C as a secondary
target for therapy after risk-stratified LDL-C levels have
been reached in patients with baseline TG >200 mg/dL
[23]. One of the key results in this study was the 17.3 %
reduction in the risk of MVCs for those attaining non-
HDL-C goals compared to those not reaching the goals.
Non-HDL-C, defined as TC minus HDL-C, is a sensitive
surrogate measure of total atherogenic lipoprotein bur-
den in serum and is a useful index for predicting the risk
of CVD, especially among patients with diabetes since it
circumvents the reliability issues associated with usingLDL-C in a diabetic population [24]. These findings hint
at a potential role for non-HDL-C in predicting risk for
microangiopathy in T2DM patients since it singularly
combines the impact of total cholesterol and its various
atherogenic lipoproteins in place of LDL-C. Furthermore,
evidence exists that after achieving LDL-C goal levels,
non-attainment of non-HDL-C target goals among T2DM
patients is markedly associated with residual risk and dys-
lipidemia [25].
Overall, the current study highlights the possible bene-
fits of treating any or all components of the lipid beyond
LDL-C alone, in order to most optimally reduce morbidity
and mortality in diabetic patients. The sensitivity ana-
lyses further confirmed the hypothesis that independently
achieving HDL-C, TG, HDL-C and TG and non-HDL-C
goals can lead to significant reductions in MVC risk
irrespective of LDL-C goal attainment. This suggests
that attainment of lipid goals other than LDL-C can
translate into incremental reductions in risk of MVCs.
Table 3 Cox Proportional Hazard Models: HDL-C, LDL-C, TG and non-HDL-C and the First Microvascular Event
Primary Risk Factors of Interest1 Lipid Panel2 Lipid Goal Attainment2
HR3 95 % CI P-value HR3 95 % CI P-value
HDL-C 0.995 0.993 - 0.997 <.0001 0.895 0.852 - 0.941 <.0001
LDL-C 1.002 1.001 - 1.002 <.0001 0.909 0.865 - 0.955 .0001
TG 1.001 1.001 - 1.001 <.0001 0.849 0.808 - 0.892 <.0001
non-HDL-C 1.003 1.003 - 1.004 <.0001 0.8270 0.788 - 0.868 <.0001
1 Four Cox proportional hazard models were run, two including HDL-C, LDL-C, and TG (lipid values and their goal attainment); the others with non-HDL-C lipid
values and goal attainment as the primary risk factor of interest.
2 The lipid panel values are derived from the last lab assessment results prior to the first microvascular (either retinopathy/nephropathy/neuropathy) event or
censorship.
3 The HRs were obtained after controlling for the demographics (age, gender and state of residence), other index characteristics (health plan and physician type), pre-
index health conditions (hypertension, obesity, heart failure, metabolic syndrome, renal disease, liver disease, ischemic heart disease, peripheral vascular disease, and
depression), proportion of days covered during the follow up by the antihypertensives (ACEs, ARBs), and proportion of days covered by lipid altering therapies (statins
[low, medium or high], niacin, ezetimibe, or fibrates [fenofibrates or genfibrozil]) between the last lipid panel measurement and event/censorship.
HR: hazard ratio; CI: confidence interval; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.
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http://www.cardiab.com/content/11/1/109Furthermore, this study lays the groundwork for conduct-
ing additional research to identify the best predictive mod-
els for estimating MVC risk (e.g., correlating Log (TG)/
HDL-C with risk for MVC) [26]. More importantly, these
study findings suggest that a gap exists between the
current practice recommendations and the appropriate
management of MVC risk among T2DM patients.
Post hoc analyses of multiple clinical trials suggest that
fenofibrate therapy impacts risk for MVC. The Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD)
study found that patients receiving fenofibrate treatment
had a reduced risk of a first and follow-up laser interven-
tion for proliferative retinopathy, lower extremity amputa-
tion, and progression to albuminaria and nephropathy
versus those on placebo [27-29]. Similarly, the Action to
Control Cardiovascular Risk in Diabetes (ACCORD)
group of studies evaluating the effect of intensive glycemic
control and combination therapy for dyslipidemia found
significantly reduced progression rates of diabetic retinop-
athy for patients who received fenofibrate versus those
who received placebo [30]. The Diabetes Atherosclerosis
Intervention Study (DAIS) reported reduced progression
of albumin excretion for fenofibrate treatment versus pla-
cebo [31]. While the confounding effect arising out of
fenofibrate usage was controlled for in the present ana-
lysis, our results underscore the relative importance of the
other components of the standard lipid profile besides
LDL-C to microangiopathy risk. They also emphasize the
importance of appropriately managing HDL-C, TG, and,Table 4 Sensitivity Analysis: Incidence of MVCs and HDL-C, LD
Attainment
LDL goal attained
HDL goal (yes vs. no) TG goal (yes vs. no
Yes 0.804 (0.75 - 0.862) 0.788 (0.735 - 0.845
No 0.853 (0.802 - 0.907) 0.785 (0.738 - 0.835
HR: hazard ratio; CI: confidence interval; LDL-C: low-density lipoprotein cholesterol;non-HDL-C levels through therapeutic lifestyle changes
and appropriate pharmacotherapy.
With the increasing prevalence of T2DM adding to
the clinical and overall healthcare burdens of patients
and society, there is an urgent need for optimal and
timely disease management. In the absence of guidelines
for the management of lipid subfraction levels to reduce
the risk of diabetic microangiopathy, the control of these
modifiable risk factors may lead to reducing or delaying
the incidence of T2DM-related MVCs [29]. These find-
ings suggest that there may be a need to simultaneously
target improvements in multiple lipid subfractions be-
yond LDL-C, and that pursuing overall lipid subfraction
improvements may lead to benefits beyond macrovascu-
lar risk reduction for patients with T2DM.
Limitations
Claims-based studies are subject to important limita-
tions. The coding of claims is susceptible to lack of spe-
cificity, miscoding, improper sequencing, and clerical
errors. The study may be hindered by incomplete data in
terms of insufficient longitudinal capture of relevant
claims (e.g. lack of capture of pre-existing MVCs prior
to the start of the patient's health plan eligibility) and/or
capture of information that is unobservable in an admin-
istrative claims database (e.g. use of over-the-counter
medications). Unobservable factors that may influence
outcomes are generally omitted when using claims data
and in the case of this study, the presence of suchL-C, TG and non-HDL-C Stratified Across LDL-C Goal
HR (95 % C.I)
) HDL+ TG goals (yes vs. no) non-HDL goal (yes vs. no)
) 0.758 (0.705 - 0.816) 0.785 (0.717 - 0.86)
) 0.787 (0.738 - 0.84) 0.787 (0.711 - 0.871)
HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.
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between comparison groups. Important contributory fac-
tors of T2DM, such as genetics or alcohol or estrogen
use, could not be captured in these data [20]. Because
the data used in this study pertain to largely working-
age subjects within a managed care population, the find-
ings may not be readily replicable or generalizable to the
entire T2DM patient population.
The mean follow-up period in our study was less than
2 years, which may not have been of sufficient duration
to determine the onset of MVCs attributable to lipid
subfractions. However, because this was an observational
claims study, requiring a fixed follow-up period of 4 to
5 years for these patients would have forced survival and
subsequently introduced bias. As such, follow-up dur-
ation was accounted for as a variable in the survival ana-
lysis for risk estimation of MVCs. These inherent study
design limitations render the findings hypothesis-
generating and need to be confirmed in a prospective,
randomized clinical trial.
Conclusion
This study demonstrates significant independent associa-
tions among HDL-C, TG and non-HDL-C with risk for
microvascular events following the diagnosis of T2DM.
Attaining ADA goals for non-HDL-C, HDL-C, and TG
levels were significantly associated with a reduced risk of
MVCs. There was no clear association, however, be-
tween the attainment of the ADA goal for LDL-C and
microvascular event risk. These findings suggest that to
reduce risk for both macrovascular and microvascular
events among patients with T2DM, all components of
the lipid profile should be treated to ADA-specified tar-
get levels. These findings need to be validated in a pro-
spective, randomized clinical trial.
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